Play all audios:
With the surge in COVID-19 cases and the threat the double mutant virus poses to the general population, it is impossible to ignore the current crisis. Scientists and medical professionals
are looking for different ways and means to contain the situation, while authorities are emphasizing on the need to follow all COVID measures. That said, during such a time, a study has
revealed that medical inhalers used by asthmatic patients can reduce the replication of SARS-CoV-2 in lung cells and limit the risk of hospitalisation in COVID patients. The study According
to the study conducted by the University of Oxford, a common drug used to treat asthma, can help fasten the process of recovery in COVID-19 patients. The study published in the Lancet
journal found that inhaled glucocorticoids can reduce the risk of severe COVID and hospitalisation amongst people infected with SARs-COV-2 infections. Similarly, earlier studies from China,
Italy and other countries had suggested the same claiming patients with asthma and chronic obstructive pulmonary disease (COPD) were less likely to be hospitalised. Can inhaled budesonide
ensure shorter recovery period? The Lancet study involved 146 participants from the United Kingdom, half of whom were asked to use inhalers with budesonide and received the COVID care. The
team of researchers found that inhaled budesonide, when given in regulated doses and for a short period of time, could be effective in treating severe COVID and could also ensure a shorter
recovery period. Additionally, it was found that the duration of fever in COVID patients was much lower in the group that received the budesonide as compared to those who were only limited
to the usual care group. Patients who received inhaled budesonide reported less signs of persistent Covid-19 symptoms beyond 14 days. The conclusive report suggested that inhaled budesonide
reduced the probability of hospitalisation and also reduced the risk of severe infections in COVID-19 patients. Also See: How To Take Covid Vaccine